|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||130.82 - 132.62|
|52 Week Range||121.00 - 148.99|
|Beta (3Y Monthly)||0.73|
|PE Ratio (TTM)||21.81|
|Earnings Date||Oct 15, 2019|
|Forward Dividend & Yield||3.80 (2.94%)|
|1y Target Est||149.76|
Biotech stocks continued to languish for a third straight week. Negative broader market sentiment and company-specific weakness weighed down on the sector. Pfenex Inc (NYSE: PFNX ) received FDA approval ...
The coming week’s docket of economic reports and earnings releases comes just following the Trump administration’s announcement of a partial trade deal with China late last week.
Health authorities in Democratic Republic of Congo will introduce a Johnson & Johnson Ebola vaccine in November in the country's eastern provinces, to counter the current outbreak, they said. The J&J vaccine will complement another vaccine manufactured by Merck, which has been administered to more than 225,000 people. It requires two injections eight weeks apart, unlike the Merck vaccine, which requires a single shot.
Johnson & Johnson, Nucor, Illinois Tool Works, Pentair, and W.W. Grainger have kept their dividends intact and growing for years, making them solid investment considerations for a low-rate world
A damages award of $8bn against Johnson & Johnson this week proved the point. Carl Tobias, a law professor at the University of Richmond, points out that steep awards dished out by US juries are almost always reduced on appeal. A 2003 Supreme Court ruling means punitive damages should usually be no more than 10 times compensatory damages.
Investors may have overreacted to Johnson & Johnson’s recent spate of multbillion-dollar losses in personal injury cases. J&J is big and aggressive, and can weather the legal awards, which may be less than the estimates.
Johnson & Johnson expects to spend $11 billion on innovation this year, including some research taking place in and around Philadelphia.
FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.
With most blue-chip companies earnings scheduled over the coming weeks and sentiments being mixed, investors should closely monitor the movement of the Dow ETF and grab an opportunity that arises from a surge in any of the 30 stocks.
Bernstein analysts contend the New Brunswick, N.J., giant's shares are now `historically cheap' and the news from the lawsuits it's facing has been factored into the stock price.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 10.) The Medicines Company (NASDAQ: MDCO ) Ra ...
J&J's (JNJ) cancer drugs are expected to contribute significantly to third-quarter 2019 earnings. Generic/biosimilar headwinds are expected to hurt Pharma unit's sales.
JNJ stock slipped Wednesday after a jury ruled the Dow Jones pharmaceutical company must pay $8 billion after its antipsychotic drug, Risperdal, caused male teens to develop breast tissue.
Moody's Investors Service commented that a Pennsylvania jury decision to award $8 billion in punitive damages to a plaintiff alleging damages from Johnson & Johnson's drug Risperdal is credit negative. For additional information, please refer to Moody's Issuer Comment on Johnson & Johnson available on www.moodys.com. This publication does not announce a credit rating action.
Wall Street rose for the first time in three sessions on Wednesday with technology stocks providing a boost, as a report that China was open to a partial trade deal soothed investor nerves ahead of high-level talks on Thursday. Shares in Microsoft Corp and Apple Inc rose more than 1% and were among the biggest boosts to the S&P 500.
JNJ stock is forming a flat base. But several lawsuits claiming Johnson & Johnson baby powder caused cancer are weighing on shares. So, is the Dow Jones component a buy right now?
Philadelphia jury orders J&J (JNJ) to pay punitive damages of $8 billion to a man who claims that the use of Risperdal caused him to develop breasts.
A jury handing down an $8 billion verdict against Johnson & Johnson, saying the company failed to properly warn patients about a side-effect to its anti-psychotic drug that caused breast growth in men. Yahoo Finance's Heidi Chung joins Akiko Fujita to discuss.
Drug Giant Johnson & Johnson has been ordered to pay $8 billion in damages to a man who grew breast tissue after taking anti-psychotic drugs as a child. A new book by journalist Ronan Farrow is shedding new light on allegations against former Today Show anchor Matt Lauer. Yahoo Finance’s Jen Rogers breaks down the latest news stories on On the Move.
Excessive - That's what Wall Street analysts are calling the $8 billion - a jury ordered Johnson & Johnson to pay in punitive damages. The ruling involves a man who claimed the company failed to warn young men that they could grow breasts if they used the antipsychotic drug Risperdal. Analysts point out that the plaintiff had already been awarded $680,000 in compensatory damages over his claims. And they note that the drug's label mentions breast growth as a side effect. Analysts and legal experts say the punitive damages will likely be reduced on appeal. J&J called the award "grossly disproportionate with the initial compensatory award" and said it's confident it would be overturned. J&J's shares fell in early trading Wednesday, reflecting investor fears of escalating litigation costs as the company battles more than 13,000 lawsuits tied to that drug. It's the latest setback in court for J&J. In August, the state of Oklahoma ordered it to pay $572 million for its role in fueling the opioid epidemic. Last year, a Missouri jury ordered it to pay $4.7 billion to 22 women who alleged its talc-based products caused them to develop ovarian cancer.
Yahoo Finance's Heidi Chung, Julia La Roche, Ethan Wolff-Mann, and Alexis Keenan discuss the latest pharmaceutical suit for Johnson & Johnson.